64 results about "Intercellular adhesion molecule" patented technology

Compositions and methods are provided for the treatment and diagnosis of diseases amenable to treatment through modulation of the synthesis or metabolism of intercellular adhesion molecules. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and endothelial leukocyte adhesion molecule-1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a transcription initiation site, a translation initiation site, 5'-untranslated sequences, 3'-untranslated sequences, and intervening sequences. Methods of treating animals suffering from disease amenable to therapeutic intervention by modulating cell adhesion proteins with an oligonucleotide specifically hybridizable with RNA or DNA corresponding to one of the foregoing proteins are disclosed. Methods for treatment of diseases responding to inhibition of cell adhesion molecules are disclosed.

The invention discloses a preparation method of human cytokine-induced killer cells, comprising the following steps: coating a cell culture flask with a coating buffer containing effective amount of fusion protein and human CD3 monoclonal antibody before culturing precursor cells of human CIK cells, and adding the human CD3 monoclonal antibody in the whole process of inducing and culturing the human CIK cells, wherein the fusion protein is human intercellular adhesion molecule-1 functional domain and human fibronectin functional domain fusion protein, and the concentration of the human CD3 monoclonal antibody in the cell culture solution is lower than the concentration of the human CD3 monoclonal antibody in the coating buffer. According to the invention, ex-vivo expansion efficiency of peripheral blood mononuclear cells and the proportion of CD3 / CD56 double positive cells in the CIK cells are significantly raised, the cytotoxicity activity of the CIK cells is enhanced, thus the effect of cellular immunity treatment is raised.

Disclosed is a multi-step process for preparing a compound of Formula I:wherein R1 to R3 are as defined herein. The compounds of formula I inhibit the binding of human intercellular adhesion molecules to the Leukointegrins. As a result, these compounds are useful in the treatment of inflammatory and immune cell-mediated diseases.

The invention discloses a chemiluminescence immunoassay kit for quantitative detection of a soluble intercellular adhesion molecule-1 and a detection method. The kit contains a 96-well plate which is pre-coated with an anti-intercellular adhesion molecule-1 monoclonal antibody and the following bottled reagents: a phosphate wash solution, a blocking solution, a sample dilution solution, an intercellular adhesion molecule-1 standard solution, a horseradish peroxidase-labeled anti-intercellular adhesion molecule-1 polyclonal antibody IgG and a luminescent substrate, namely a luminal luminescent solution and quality control serum. The kit disclosed by the invention has the advantages of accurate and objective determination result of the soluble intercellular adhesion molecule-1 in human serum, simple and convenient method and easiness in popularization and application. The kit can reflect the autoimmune state in a patient with autoimmune thyroid disease can be used as a reference index for diagnosis of the autoimmune thyroid disease, and further has important significance for understanding the autoimmune active degree, predicting the occurrence of Graves disease and the recurrence of Graves hyperthyroidism, and determining reasonable treatment source, drug withdrawal time and other aspects.

The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of ICAM-1 gene expression and / or activity, and / or modulate a ICAM-1 gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against ICAM-1 gene expression.